Physician profile
Mark Cohen
NPI 1609371145
$3,935.65
in general payments reported to CMS, 2019-2025
21 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,359 · 2023: $160 · 2024: $1,309 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,577.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $943.84 | 2022-2025 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $456.48 | 2024-2025 | Relistor |
| Nevro Corp. | $418.78 | 2022-2024 | Senza |
| Abbvie INC. | $299.86 | 2023-2025 | Qulipta, Ubrelvy |
| Valinor Pharma, LLC | $290.45 | 2024-2025 | Movantik |
| Galderma Laboratories, L.P. | $235.40 | 2024-2025 | Nemluvio |
| Pfizer INC. | $218.74 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $178.14 | 2024-2025 | |
| Eisai INC. | $153.42 | 2024-2025 | |
| Boston Scientific Corporation | $115.21 | 2022 | |
| Scilex Pharmaceuticals INC. | $93.13 | 2025 | |
| Indivior INC. | $81.63 | 2024-2025 | Sublocade |
| Saluda Medical Americas, INC. | $75.31 | 2024 | Evoke |
| Depuy Synthes Sales INC. | $73.70 | 2023-2024 | Orthovisc |
| Krystal Biotech INC | $65.47 | 2024 | Vyjuvek |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $62.59 | 2024-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $51.96 | 2024-2025 | |
| Biogen, INC. | $38.10 | 2024-2025 | Vumerity, Leqembi |
| Curonix LLC | $35.77 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Forte Bio-Pharma LLC | $29.89 | 2025 | Prolate, Tanlor, Nalocet |
| Heron Therapeutics, INC. | $17.78 | 2023 | Zynrelef |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.